Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Shire reveals “groundbreaking” anaemia treatment

Shire reveals “groundbreaking” anaemia treatment

16th June 2006

Shire Pharmaceuticals, the UK’s third largest drugs company, has revealed the first results of studies for Dynepo, a treatment for renal anaemia.

It is designed for patients who are showing signs of renal failure. In these cases, red blood cell production in the body is often impaired because the kidney fails to produce erythropoietin, a hormone that stimulates bone marrow to produce red blood cells. Dynepo (epoetin delta) is administered to replace the role of erythropoietin.

In one study, it was found that Dynepo “corrects and maintains” haemoglobin levels in patients suffering from anaemia and chronic kidney disease (CKD) who are on dialysis.

Another study demonstrated that Dynepo reduces the amount of carbohydrate residue in the body – something that can trigger an immune response – in comparison to other erythropoietin treatments.

Dr Iain Macdougall, consultant nephrologists and honorary senior lecturer from the renal unit in King’s College Hospital, remarked: ” There is a pressing need for further research into the differences between Dynepo and conventional erythropoietin treatments that are not produced in human cell lines.

“It will be fascinating to see whether these differences will ultimately translate into specific benefits for patients with CKD who are suffering from anaemia.”

Shire’s vice-president of global medical affairs, Dr Raymond Pratt, added: “Shire is proud to be involved in products produced by this ground-breaking gene activation technology.”

Basingstoke-based Shire specialises in drugs for central nervous system disorders, gastrointestinal diseases. It also produces drugs for attention deficit hyperactivity disorder and Alzheimer’s disease.

track© Adfero Ltd

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.